Karishma Kapoor, Vinay Pandit, Upendra Nagaich
Karishma Kapoor2, Vinay Pandit2, Upendra Nagaich1*
1Amity Institute of Pharmacy, Amity University, Sector 125, Noida, UP 201313.
2Laureate Institute of Pharmacy, Kathog, Kangra 177101 HP India.
Volume - 14,
Issue - 2,
Year - 2021
Late investigation of complex and shifted parts of rheumatoid joint pain (RA) is prompting the advancement of the more viable focuses for pharmaceutical methodology than it was previously. Current treatment for RA much of the time incorporates the utilization of non-steroidal anti-in?ammatory drugs, notwithstanding the extreme antagonistic effects. Local application and consolidation of the medications in cubosomes based formulations may diminish those reactions and improve the efficacy of medications by decreasing the accessibility of them in systemic dissemination and expanding deposition and retention time at the in?ammed sites. MTX cubosomes were formulated using Monoolein and Poloxamer-407 and water. The ex vivo skin saturation study was done with the assistance of rat abdominal skin using vertical Franz dispersion cell using PBS and samples were withdrawn and analyzed at defined intervals. In-vivo studies were performed on Female Wistar rats using Bovine type II collagen (CII; Chondrex, Redmond, WA, USA) arrangement in 0.1N acetic acid was emulsi?ed with Freund's adjuvant and the emulsion was imfused subcutaneously at the bottom of the tail. Ex vivo skin permeation using rat abdominal study, primary stage which was quick showed MTX penetration at the first 2h pursued by more slow medication infiltration during the following examined hours. Histopathological studies showed correlated results upon evaluation. Inflammed paw thickness was measured each and there was a considerable decrease in the paw size after the rats were treated with this novel delivery system.: The relative bioavailability of both the formulation was found to be 202.38% and 192.54% respectively, therefore the system was found to be more reliable and non-invasive for topical delivery.
Cite this article:
Karishma Kapoor, Vinay Pandit, Upendra Nagaich. Topical Methotrexate Cubosomes in Treatment of Rheumatoid Arthritis: Ex-Vivo and In-Vivo Studies. Research J. Pharm. and Tech. 2021; 14(2):991-996. doi: 10.5958/0974-360X.2021.00177.3
1. Heiberg, T., and Kvien, T. K.. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum.2002; 47, 391–397.
2. Minnock, P., FitzGerald, O., and Bresnihan, B.. Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status. Rheumatology.2003; 42:995–1000.
3. Aida Turturro Brings Rheumatoid Arthritis Awareness Campaign to Philadelphia". Market Wire. 2005.
4. Baratelle, Anna M, Desiree van der Heijde. Radiographic Imaging End Points in Rheumatoid Arthritis Trials. Clinical Trials, Clinical Trials in Rheumatoid Arthritis and Osteoarthritis, 2008; pp201-221.
5. Suter LG, Fraenkel L, Braithwaite RS. Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis. Arthritis Care Res (Hoboken), May; 63(5): 675-88
6. Le Guellec C, Blasco H, Benz I, Hulin A. Niveau de preuve du suivithérapeutiquepharmacologique du méthotrextae au décours de son administration à haute dose. Thérapie. 2010; 653: 163-9.
7. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm. 2004;270:119–25.
8. Amidon GL, Lennern¨as H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res.1995; 12:413–20.
9. Safety Data Sheet. Methotrexate.Availabe at www.usp. org/pdf/ EN/referenceStandards/msds/1414003.pdf.
10. Toxicology Data Network Methotrexate (xxx = Methotrexate). Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+ hsdb:@term+@DOCNO+3123. Updated May 2011.Accessed December 14, 2013.
11. Lee SJ, Kavanaugh A. Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Cl Rh. 2003;17:811–29.
12. Cutolo M. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001; 60:729–35.
13. Lee DM, Weinblatt ME. Rheumatoid arthritis.Lancet. 2001;358:903–11.
14. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol.1989; 16: 313-20.
15. Z. Wang, et al., Berberine ameliorates collagen-induced arthritis in rats associated with anti-inﬂammatory and anti-angiogenic effects, Inﬂammation. 2014; 37:1789–98.
16. J.H. Choi, et al., Gallium nitrate ameliorates type II collagen-induced arthritis in mice, Int. Immunopharmacol. 2014;20: 269–75.
17. Neha, M.M. Ansari, H.A.Khan, Yohimbine hydrochloride ameliorates collagen type II-induced arthritis targeting oxidative stress and inﬂammatory cytokines in Wistar rats, Environ. Toxicol. 32 (2017) 619–629.
18. S. Umar, et al., Piperine ameliorates oxidative stress, inﬂammation and histological outcome in collagen induced arthritis, Cell. Immunol. 284 (2013) 51–59.
19. Helledi, L.S. and Schubert, L. (2001) Release kinetics of acyclovir from a suspension of acyclovir incorporated in a cubic phase delivery system. Drug Dev. Ind. Pharm. 27, 1073–1081
20. Bender, J. et al. (2005) Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J. Control. Release 106, 350–360
21. Esposito, E. et al. (2005) Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm. Res. 22, 2163–2173
22. Lopes, L.B. et al. (2005) Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. Eur. J. Pharm. Biopharm. 60, 25–30
23. Lopes, L.B. et al. (2006) Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. Eur. J. Pharm. Biopharm. 63, 146–155
24. Lopes, L.B. et al. (2006) Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Pharm. Res. 23, 1332–1342
25. Lopes, L.B. et al. (2007) Enhancement of skin penetration of vitamin K using monoolein-based liquid crystalline systems. Eur. J. Pharm. Sci. 32, 209–215
26. Cohen-Avrahami, M. et al. (2010) HII mesophase and peptide cell-penetrating enhancers for improved transdermal delivery of sodium diclofenac. Colloid Surf. B 77, 131–138
27. Yariv, D. et al. (2010) In vitro permeation of diclofenac salts from lyotropic liquid crystalline systems. Colloid Surf. B 78, 185–192.